RxDoctor Payments Data

Edward Burke, MD

Internal Medicine · Fredericktown, MONPI 1306885157

Payments from drug & device makers

$3,418in general payments, 2019–2025

Across 195 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$822
  • Lundbeck LLC$223
  • Astellas Pharma US Inc$207
  • Otsuka America Pharmaceutical, Inc.$193
  • Teva Pharmaceuticals USA, Inc.$181
  • Mimedx Group, Inc.$181
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,11691%
  • Education$3029%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,418 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$156
Medicare patients
18
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine36$306,411
Invega SustennaPaliperidone Palmitate69$247,597
EliquisApixaban639$196,021
Austedo XrDeutetrabenazine24$166,063
Trelegy ElliptaFluticasone/Umeclidin/Vilanter239$154,119
JardianceEmpagliflozin436$133,381
OzempicSemaglutide100$103,515
Abilify MaintenaAripiprazole29$85,867
XareltoRivaroxaban304$83,407
TrulicityDulaglutide55$61,057
MyrbetriqMirabegron263$52,027
XifaxanRifaximin27$43,037
VraylarCariprazine Hcl51$38,233
LinzessLinaclotide70$37,994
GemtesaVibegron142$37,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$181$472,47460 claims
Johnson & JohnsonInvega Sustenna, Xarelto, Risperdal Consta$97$363,110394 claims
PfizerEliquis$71$196,021639 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$160$186,834309 claims
Boehringer IngelheimJardiance, Combivent Respimat$31$148,322465 claims
Novo NordiskOzempic$130$103,515100 claims
AbbVieVraylar, Linzess, Restasis$822$87,569143 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$193$85,86729 claims
Lilly USA, LLCTrulicity$90$61,05755 claims
Astellas Pharma US IncMyrbetriq$207$52,027263 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$13$43,03727 claims
Sumitomo Pharma America, Inc.Gemtesa$54$37,348142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Fredericktown

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →